• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Class 2 Device Recall The TaqPath RTPCR COVID19 Kit with Applied Biosystem's COVID19 Interpretive Software

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

New Search Back to Search Results
  Class 2 Device Recall The TaqPath RTPCR COVID19 Kit with Applied Biosystem's COVID19 Interpretive Software see related information
Date Initiated by Firm August 06, 2020
Create Date September 17, 2020
Recall Status1 Terminated 3 on May 05, 2022
Recall Number Z-2979-2020
Recall Event ID 86204
Product Classification Reagents, 2019-novel coronavirus nucleic acid - Product Code QJR
Product The TaqPath RT-PCR COVID-19 Kit with Applied Biosystem's COVID-19 Interpretive Software v2.0 or v2.2 (used with the QuantStudio Real-Time PCR platforms), includes the assays and controls for a multiplex real-time RT-PCR test for the qualitative detection of RNA from SARS-CoV-2 in upper respiratory specimens and bronchoalveolar lavage specimens from individuals suspected of COVID-19 by their healthcare provider. The test is interpreted by COVID-19 Interpretive Software
Code Information Product SKU: Product Lot/Serial#: Release Date:  100093765 Version 1.2 (EUA) 28-APR-20  100087427 Version 2.2 (EUA) 11-MAY-20  100093771 Version 1.2 (CE-IVD) 28-APR-20  100094318 Version 2.2 (CE-IVD) 19-MAY-20   Applied Biosystems" COVID-19 Interpretive Software Version 1.2 was the first version of software developed in a dedicated CE-IVD Edition.  Previous versions are shared with the FDA-EUA version of the device. 
Recalling Firm/
Life Technologies Corporation
6055 Sunol Blvd
Pleasanton CA 94566-7853
For Additional Information Contact Ron O'Brien
Manufacturer Reason
for Recall
COVID-19 Interpretive Software issues that may cause: 1) the risk of invalid or inconclusive tests/false negative and potentially increasing the retesting burden on customers. 2) false positive results due to improper vortexing.
FDA Determined
Cause 2
Action On 08/06/2020, the firm sent an "Urgent: Medical Device Field Correction" notification to customers via email and a follow-up letter via FedEx informing them of two issues associated with COVID-19 interpretive software: 1) A small number of poorly extracted patient samples were called valid by the interpretive software, related to current MS2 assay analysis settings. This issue can potentially cause a weakly positive sample that is prepared by suboptimal extraction to be falsely called a valid negative sample, thereby constituting a False Negative. And 2) The MS2 assay, which detects the Internal Positive Control (IPC), was erroneously called amplified in a small percentage of Positive Control (PC) samples. This issue caused a plate to be designated invalid, thereby requiring unnecessary retesting of an entire batch of samples. The firm is not requesting return of product. The issue is related to software and improper mixing/vortexing of the qPCR plates. Customer are instructed to: -Notify all Applied Biosystems COVID-19 Interpretive Software users in their facility of this communication. -Stop using Applied Biosystems COVID-19 Interpretive Software v1.2, v2.0 and v2.2. -Go to www.thermofisher.com/educationconnect and sign in with their thermofisher.com username and password. Type in the subscription code C19CKEUAFIS1323 to access and complete the training. The customer will be required to pass an exam and acknowledge that they have reviewed information to upgrade the COVID-19 Interpretive Software. Re-registration is required for this upgrade. For full instructions to learn how to access the new version of the software please read the recalling firm's EducationConnect welcome letter or watch the quick video tutorial. -Read and implement the vortexing recommendations added to the latest release of the Instructions for Use  available on the product page TaqPath COVID-19 EUA IFU to prevent insufficient mixing and/or centrifugation. -Sign and return Ac
Quantity in Commerce NA
Distribution US: AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, MS, NC, NH, NJ, NM, NY, NV, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, and WV. OUS: Afghanistan, Algeria, Argentina, Australia, Austria, Azerbaijan, Bahrain, Bangladesh, Belarus, Botswana, Brazil, Cameroon, Canada, Cypress, Estonia, France, Georgia, Germany, Greece, Guadeloupe, Hungary, India, Indonesia, Ireland, Israel, Italy, Kenya, Kuwait, Lebanon, Mozambique, Namibia, New Zealand, Oman, Philippines, Poland, Portugal, Qatar, Romania, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, United Arab Emirates, United Kingdom, United Republic of Tanzania, and Vietnam.
Total Product Life Cycle TPLC Device Report

1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.
3 For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.